Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2017 2
2018 1
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
Poly(lactic acid)-based particulate systems are promising tools for immune modulation.
Peres C, Matos AI, Conniot J, Sainz V, Zupančič E, Silva JM, Graça L, Sá Gaspar R, Préat V, Florindo HF. Peres C, et al. Acta Biomater. 2017 Jan 15;48:41-57. doi: 10.1016/j.actbio.2016.11.012. Epub 2016 Nov 4. Acta Biomater. 2017. PMID: 27826003 Review.
Its attractive properties of biodegradability and biocompatibility in vivo have contributed in a meaningful way to the approval of different products by the FDA and EMA for a wide range of biomedical and pharmaceutical applications, in the past two decades. ...
Its attractive properties of biodegradability and biocompatibility in vivo have contributed in a meaningful way to the approval of different …
Effect of European Medicines Agency's restrictions on trimetazidine utilization in Portugal.
Pinto D, Silva A, Heleno B, Rodrigues DS, Santos I, Caetano PA. Pinto D, et al. Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):962-968. doi: 10.1002/pds.4585. Epub 2018 Jul 10. Pharmacoepidemiol Drug Saf. 2018. PMID: 29992780
PURPOSE: Following safety concerns regarding trimetazidine, the European Medicines Agency (EMA) recommended restrictions on its use. Our objective was to determine the impact of regulatory actions on trimetazidine utilization in Portugal. ...RESULTS: Two interruption perio …
PURPOSE: Following safety concerns regarding trimetazidine, the European Medicines Agency (EMA) recommended restrictions on its use. …
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.
Batista S, Nunes CC, Cerqueira JJ, Martins Silva A, Correia de Sá J, Ferreira J, Mendonça MT, Pinheiro J, Salgado V, Correia AS, Sequeira J, Costa A, Sousa L. Batista S, et al. Neurol Sci. 2021 May;42(5):1995-2003. doi: 10.1007/s10072-020-04726-6. Epub 2020 Sep 30. Neurol Sci. 2021. PMID: 32997282 Free PMC article.
BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portu …
BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple scler …
Blockade of bradykinin receptors or angiotensin II type 2 receptor prevents paclitaxel-associated acute pain syndrome in mice.
Zanata GC, Pinto LG, da Silva NR, Lopes AHP, de Oliveira FFB, Schivo IRS, Cunha FQ, McNaughton P, Cunha TM, Silva RL. Zanata GC, et al. Eur J Pain. 2021 Jan;25(1):189-198. doi: 10.1002/ejp.1660. Epub 2020 Oct 6. Eur J Pain. 2021. PMID: 32965065
ACE inhibitors (captopril and enalapril), antagonists for angiotensin II type 1 (losartan) and type 2 ([AT2R]; PD123319 and EMA 401) receptors were administrated prior the treatment with PCX. ...
ACE inhibitors (captopril and enalapril), antagonists for angiotensin II type 1 (losartan) and type 2 ([AT2R]; PD123319 and EMA 401) …
A critical evaluation of different parameters for estimating pharmaceutical exposure seeking an improved environmental risk assessment.
Pereira AMPT, Silva LJG, Lino CM, Meisel LM, Pena A. Pereira AMPT, et al. Sci Total Environ. 2017 Dec 15;603-604:226-236. doi: 10.1016/j.scitotenv.2017.06.022. Epub 2017 Jun 23. Sci Total Environ. 2017. PMID: 28628814
A critical evaluation of the European Medicines Agency (EMA) Guideline on Environmental Risk Assessment (ERA) was performed on 16 of Portugal's most consumed pharmaceuticals in wastewater effluents (WWEs), the main route for aquatic contamination. ...The results showed tha …
A critical evaluation of the European Medicines Agency (EMA) Guideline on Environmental Risk Assessment (ERA) was performed on 16 of …